May 6,2025
Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy
READ MORE
January 31,2023
Novaremed announces publication of pharmacological profile of MP-101, a clinical development candidate for the prevention of chemotherapy-induced peripheral neuropathy
READ MORE
July 21, 2022
Novaremed enters into an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore
READ MORE
June 23, 2022
Novaremed announces publication of Phase 1 and Phase 2a study data with NRD.E1 demonstrating the potential of this investigational non-opioid pain treatment
READ MORE
December 21, 2021
Novaremed’s Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain
READ MORE
September 7, 2021
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
READ MORE
January 28, 2021
Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets
READ MORE
December 22, 2020
Novaremed receives Fast Track Designation from the FDA for NRD135S.E1 for treatment of Painful Diabetic Peripheral Neuropathy
READ MORE
September 15, 2020
Novaremed Announces Closing of a New Financing, Publication of PCT Patent Application and Participation at IASP Virtual Conference on Pain & Expo
READ MORE